Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.

MLA

Lopez-Anglada, Lucia, et al. “Prognostic Utility of Serum Free Light Chain Ratios and Heavy-Light Chain Ratios in Multiple Myeloma in Three PETHEMA/GEM Phase III Clinical Trials.” PloS One, vol. 13, no. 9, Sept. 2018, p. e0203392. EBSCOhost, https://doi.org/10.1371/journal.pone.0203392.

APA

Lopez-Anglada, L., Cueto-Felgueroso, C., Rosiñol, L., Oriol, A., Teruel, A. I., Lopez de la Guia, A., Bengoechea, E., Palomera, L., de Arriba, F., Hernandez, J. M., Granell, M., Peñalver, F. J., Garcia-Sanz, R., Besalduch, J., Gonzalez, Y., Martinez, R. B., Hernandez, M. T., Gutierrez, N. C., Puerta, P., … Martinez-Lopez, J. (2018). Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. PloS One, 13(9), e0203392. https://doi.org/10.1371/journal.pone.0203392

Chicago

Lopez-Anglada, Lucia, Cecilia Cueto-Felgueroso, Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Ana Lopez de la Guia, Enrique Bengoechea, et al. 2018. “Prognostic Utility of Serum Free Light Chain Ratios and Heavy-Light Chain Ratios in Multiple Myeloma in Three PETHEMA/GEM Phase III Clinical Trials.” PloS One 13 (9): e0203392. doi:10.1371/journal.pone.0203392.